Disclosures for "GLP-1-related Antihyperglycemic Medication Use is Associated with Shorter Survival in Patients with Amyotrophic Lateral Sclerosis and Diabetes Mellitus"
-
Dr. Lee has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Lee has received personal compensation in the range of $0-$499 for serving as a Consultant for Amylyx. Dr. Lee has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Regeneron. The institution of Dr. Lee has received research support from CReATe consortium/American Brain Foundation. The institution of Dr. Lee has received research support from NIH.
-
Mrs. Stolwyk has nothing to disclose.
-
Dr. Harms has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Harms has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Muscular Dystrophy Association. Dr. Harms has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Invitae. Dr. Harms has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Variant Bio. Dr. Harms has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sarepta. Dr. Harms has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amylyx. Dr. Harms has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for uniQure. Dr. Harms has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Littlepage Booth. Dr. Harms has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for O'Connor First. Dr. Harms has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Searcy Denney. Dr. Harms has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Ford, Parshall & Baker LLC . The institution of Dr. Harms has received research support from ALS Association. The institution of Dr. Harms has received research support from Ionis. The institution of Dr. Harms has received research support from ALS Finding a Cure. The institution of Dr. Harms has received research support from Target ALS.
-
Dr. Andrews has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Andrews has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Wave Life Sciences. Dr. Andrews has received personal compensation in the range of $0-$499 for serving as a Consultant for Cytokinetics. Dr. Andrews has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Apellis . Dr. Andrews has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Revalasio . Dr. Andrews has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amylyx. Dr. Andrews has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AL-S Pharma. Dr. Andrews has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Andrews has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Quralis . Dr. Andrews has received personal compensation in the range of $500-$4,999 for serving as an officer or member of the Board of Directors for Neurosense. Dr. Andrews has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for Akava. The institution of Dr. Andrews has received research support from Amylyx. The institution of Dr. Andrews has received research support from Biogen . The institution of Dr. Andrews has received research support from Cytokinetics . The institution of Dr. Andrews has received research support from NIH . The institution of Dr. Andrews has received research support from Biohaven/Platform Trial. The institution of Dr. Andrews has received research support from Clene/Platform Trial . The institution of Dr. Andrews has received research support from Ra Pharma/Platform Trial . The institution of Dr. Andrews has received research support from Prilenia/Platform Trial . Dr. Andrews has received research support from ALS Association . Dr. Andrews has a non-compensated relationship as a Board of Trustee Member with ALS Association that is relevant to AAN interests or activities.
-
Ms. Hwang has nothing to disclose.
-
Dr. Shneider has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alnylam. Dr. Shneider has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Shneider has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ProJenX. Dr. Shneider has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Regeneron. Dr. Shneider has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for GLG. Dr. Shneider has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Guidepoint. The institution of Dr. Shneider has received research support from Merck Sharp & Dohme. The institution of Dr. Shneider has received research support from National Institutes of Health. The institution of Dr. Shneider has received research support from ALS Association. The institution of Dr. Shneider has received research support from DoD/CDMRP - ALSRP. The institution of Dr. Shneider has received research support from Target ALS. The institution of Dr. Shneider has received research support from Ionis Pharmaceutical. The institution of Dr. Shneider has received research support from Cellenkos.